Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-0887
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Pharmacokinetics and Pharmacodynamics of a Novel Acetylcholinesterase Inhibitor, DMNG-3

Acta Neurobiologiae Experimentalis
MedicineNeuroscience
2016English

Pharmacokinetics and Pharmacodynamics of Two Multiple-Dose Piperacillin-Tazobactam Regimens.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1997English

Newly Diagnosed Papillary Craniopharyngioma With BRAF V600E Mutation Treated With Single-Agent Selective BRAF Inhibitor Dabrafenib: A Case Report

Oncotarget
Oncology
2019English

Effects of Mexiletine, a CYP1A2 Inhibitor, on Tizanidine Pharmacokinetics and Pharmacodynamics

Journal of Clinical Pharmacology
Pharmacology
2010English

Pharmacokinetics and Pharmacodynamics of Multiple-Dose Intravenous Nemonoxacin in Healthy Chinese Volunteers

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2014English

Pharmacokinetics and Pharmacodynamics of Suxamethonium

Anaesthesia and Intensive Care
Critical CareAnesthesiologyPain MedicineIntensive Care Medicine
1997English

Journal of Pharmacokinetics and Pharmacodynamics

Journal of Pharmacokinetics and Pharmacodynamics
Pharmacology
English

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With NSTEMI After a 180-Mg Loading Dose

Platelets
MedicineHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy